Sickle Cell Disease: Advances in Treatment

Area of Science:

• Hematology
• Genetics
• Pharmacology

Background:

• Sickle cell disease (SCD) is a significant global health burden, causing substantial morbidity and mortality.
• Historically, research and development funding for SCD has lagged behind other diseases.
• This disparity impacts economic and healthcare systems worldwide.

Purpose of the Study:

• To review current and emerging treatment modalities for sickle cell disease.
• To highlight advancements in drug development and therapeutic strategies since the late 1990s.
• To assess the potential of these interventions to improve patient outcomes.

Main Methods:

• Systematic review of literature on sickle cell disease treatments.
• Examination of targeted therapies based on SCD pathophysiology.
• Inclusion of data on stem cell transplantation and gene therapy.

Main Results:

• Several targeted therapies, including hydroxyurea, L-glutamine, and crizanlizumab, are available or emerging.
• These agents show potential for improving survival and quality of life in SCD patients.
• Stem cell transplantation remains the only curative option; gene therapy is under investigation.

Conclusions:

• Current knowledge of SCD pathophysiology informs novel treatment approaches.
• Increased interest in SCD research is evident, but more rigorous clinical trials are needed.
• Further investigation is crucial to validate the efficacy and safety of new SCD therapies.